

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Nulojix (belatacept)

CG-DRUG-95

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Nulojix (belatacept)

APPROVAL CRITERIA

Requests for Nulojix (belatacept) may be approved if the following criteria are met:

1. Prevention of organ rejection in adult individuals receiving a kidney transplant who are Epstein-Barr virus (EBV) seropositive.

Note: Nulojix (belatacept) has a black box warning for increased risk of developing PTLD, predominately involving CNS. Individuals without immunity to EBV are at particular risk, and should not be used in seronegative or unknown EBV serostatus. Therapy should only be prescribed by providers experienced in immunosuppressive therapy and management of kidney transplant. Therapy should be received in facilities equipped and staffed with adequate laboratory and supportive medical resources. Increased susceptibility to infection and development of malignancies may result from immunosuppression. Use in individuals with liver transplants is not recommended due to an increased risk of graft loss and death.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

1. Belatacept Monograph. Lexicomp® Online, American Hospital Formulary Service® (AHFS®) Online, Hudson, Ohio. Lexi-Comp., Inc. Last updated December 13, 2012. Accessed on April 3, 2018.
2. Belatacept. In: DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated February 19, 2018. Available at: <http://www.micromedexsolutions.com>. Accessed on April 7, 2018.

PAGE 1 of 2 07/18/2018

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0212-18

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

3. Masson P, Henderson L, Chapman JR, et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014 Nov 24; 11:CD010699.
4. Nulojix [Product Information], Princeton, New Jersey. Bristol-Myers Squibb Company, May 2017. Available at: http://packageinserts.bms.com/pi/pi_nulojix.pdf. Accessed on April 7, 2018.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
 CRX-ALL-0212-18